Format

Send to

Choose Destination
J Pathol. 2016 Mar;238(4):519-530. doi: 10.1002/path.4649. Epub 2016 Jan 9.

In vitro and in vivo correlates of physiological and neoplastic human Fallopian tube stem cells.

Author information

1
The Jackson Laboratory for Genomic Medicine, Farmington, CT, USA.
2
Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA.
3
Genome Institute of Singapore, A-STAR, Singapore.
4
Departments of Molecular, Microbial and Structural Biology, University of Connecticut Health Center, Farmington, CT, USA.
5
Department of Obstetrics and Gynecology, University of Connecticut Health Center, Farmington, CT, USA.
6
Division of Obstetrics and Gynecology, National University of Singapore, Singapore.
7
MultiClonal Therapeutics, Inc, Farmington, CT, USA.
8
Department of Microbiology, National University of Singapore, Singapore.
9
Department of Biology and Biochemistry, University of Houston, TX, USA.
10
Department of Genetics and Developmental Biology, University of Connecticut Health Center, Farmington, CT, USA.
11
Center for Stem Cell & Regenerative Medicine, The University of Texas Health Science Center at Houston, TX, USA.
#
Contributed equally

Abstract

High-grade serous cancer (HGSC) progresses to advanced stages without symptoms and the 5-year survival rate is a dismal 30%. Recent studies of ovaries and Fallopian tubes in patients with BRCA1 or BRCA2 mutations have documented a pre-metastatic intramucosal neoplasm that is found almost exclusively in the Fallopian tube, termed 'serous tubal intraepithelial carcinoma' or STIC. Moreover, other proliferations, termed p53 signatures, secretory cell outgrowths (SCOUTs), and lower-grade serous tubal intraepithelial neoplasms (STINs) fall short of STIC but share similar alterations in expression, in keeping with an underpinning of genomic disturbances involved in, or occurring in parallel with, serous carcinogenesis. To gain insight into the cellular origins of this unique tubal pathway to high-grade serous cancer, we cloned and both immortalized and transformed Fallopian tube stem cells (FTSCs). We demonstrated that pedigrees of FTSCs were capable of multipotent differentiation and that the tumours derived from transformed FTSCs shared the histological and molecular features of HGSC. We also demonstrated that altered expression of some biomarkers seen in transformed FTSCs and HGSCs (stathmin, EZH2, CXCR4, CXCL12, and FOXM1) could be seen as well in immortalized cells and their in vivo counterparts SCOUTs and STINs. Thus, a whole-genome transcriptome analysis comparing FTSCs, immortalized FTSCs, and transformed FTSCs showed a clear molecular progression sequence that is recapitulated by the spectrum of accumulated perturbations characterizing the range of proliferations seen in vivo. Biomarkers unique to STIC relative to normal tubal epithelium provide a basis for novel detection approaches to early HGSC, but must be viewed critically given their potential expression in lesser proliferations. Perturbations shared by both immortalized and transformed FTSCs may provide unique early targets for prevention strategies. Central to these efforts has been the ability to clone and perpetuate multipotent FTSCs.

KEYWORDS:

Fallopian tubes; cell culture; neoplasia; ovary

PMID:
26415052
PMCID:
PMC4895925
DOI:
10.1002/path.4649
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Wiley Icon for PubMed Central
Loading ...
Support Center